EXECUTIVE DIRECTOR AGREEMENTExecutive Director Agreement • June 10th, 2016 • Key Link Assets Corp. • Retail-grocery stores • Colorado
This EXECUTIVE DIRECTOR AGREEMENT is dated March 24, 2016 (the "Agreement”) by and between Foothills Petroleum, Inc. a Nevada corporation (the “Company”), and Christopher Jarvis, an individual resident of Maryland (the “Director”).
COMMUNITY ARTS AGENCY EXECUTIVE DIRECTOR AGREEMENTExecutive Director Agreement • December 5th, 2011 • Georgia
THIS EXECUTIVE DIRECTOR AGREEMENT, made and entered into on the date set forth below between Community Arts Agency (“Employer”) with its offices located at
DRAFT AGREEMENT BETWEEN NIRLON LIMITED ANDExecutive Director Agreement • November 27th, 2020
limited Company registered under the provisions of the Companies Act, 1956 and having its Registered Office situate at Pahadi Village, Goregaon (E), Mumbai: 400 063 (hereinafter referred to as “the Company” and includes its successors and assigns thereof) of the One Part;
EXECUTIVE DIRECTOR AGREEMENTExecutive Director Agreement • March 17th, 2008 • Lecg Corp • Services-management consulting services • District of Columbia
THIS EXECUTIVE DIRECTOR AGREEMENT (this "Agreement") is entered into this 27th day of November, 2007 (the "Effective Date"), by and among LECG Corporation, a Delaware corporation, successor in interest to LECG Holding Company, LLC ("LECG Holding"), and the sole managing member of LECG, LLC (the "Company"), LECG, LLC, a California limited liability company ("LECG"), and DAVID KAPLAN (the "Executive Director").
ExpectationsExecutive Director Agreement • May 21st, 2021
-Execute the policies and goals established by the Policy and Procedures Manual and execute with fidelity the official By-laws set forth in the FFLA Constitution
EXECUTIVE DIRECTOR AGREEMENTExecutive Director Agreement • January 8th, 2007 • Wabash National Corp /De • Truck trailers • Indiana
This Executive Director Agreement (the “Agreement”), made this 1st day of January, 2007, is entered into by Wabash National Corporation (the “Company”) and William Greubel (the “Executive”).
EXECUTIVE DIRECTOR AGREEMENTExecutive Director Agreement • December 19th, 2023 • SEATech Ventures Corp. • Services-miscellaneous business services • Nevada
This EXECUTIVE DIRECTOR AGREEMENT is dated on December 14, 2023 (the “Agreement”) by and between SEATECH VENTURES CORP., a Nevada corporation (the “Company”), Tan See Meng, an individual resident of Malaysia (the “Director”).
Amended and Restated Executive Director AgreementExecutive Director Agreement • November 16th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
AGREEMENTExecutive Director Agreement • March 7th, 2024 • Texas
This Agreement for Executive Director (this "Agreement") is made effective as of the 15th day of March, 2024 (the "Effective Date") by and between Gornet Consulting LLC ("Gornet"), on the one hand, and on the other by Fort Bend County Toll Road Authority (“FBCTRA”) and Fort Bend Grand Parkway Toll Road Authority (“GPTRA,” and collectively with FBCTRA, the “Authorities,” and each individually, an “Authority”). (Gornet and the Authorities are each referred to herein as a "Party" and, collectively, as the "Parties”). The Parties agree and covenant to be bound by the terms set forth in this Agreement as follows:
HOUSING FINANCE AUTHORITY OF HILLSBOROUGH COUNTY AND MARK HENDRICKSONExecutive Director Agreement • December 5th, 2017
HILLSBOROUGH COUNTY, hereinafter referred to as the "HFA" through its members and MARK HENDRICKSON hereinafter referred to as the “DIRECTOR”:
March 7, 2019 Dear Scott,Executive Director Agreement • May 9th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This letter agreement (this “Agreement”), which shall be effective as of March 5, 2019 (the “Effective Date”), sets forth the terms of your appointment as Executive Director of Immunomedics, Inc. (the “Company”), which was effective as of February 23, 2019. As Executive Director, you will be expected to perform your duties as a member of the Board of Directors of the Company (the “Board”) as well as consult with and advise the Company’s management team at the request of the Board from time to time with respect to your knowledge, experience and expertise. This will include (1) assisting the Company’s management team with resolving the issues identified in the Complete Response Letter received from the U.S. Food and Drug Administration (the “FDA”) related to the Biologics License Application (“BLA”) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic
